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Innovations in cancer immunotherapy over the past decade have reinvigorated the field,
which currently stands poised to transform treatment of certain important cancer types. While
recent discoveries in immunotherapy have occurred in an era of intense focus on precision
medicine—spurred in large part by advances in sequencing technologies allowing for unprece-
dented insights into individual and tumor genomes—the field of cancer immunotherapy is
rooted in a history that is anything but precise. The idea that the immune system could be
used to target cancer has existed for over a century. In the 1890s, William Coley provided a
spark by noting a connection between spontaneous tumor regressions and concurrent bacte-
rial infections [1]. Suspecting an immune mechanism, Coley and many others in the decades
that followed experimented with live bacteria, toxins, vaccines, and countless other agents to
coax the immune system to attack cancer, yielding only a tiny number of positive responses
and little understanding of the underlying immune mechanisms. As recently as 2010, immu-
notherapy remained a strikingly imprecise endeavor, with the only United States Food and
Drug Administration (FDA)-approved cancer immunotherapies being a pair of systemic cyto-
kines—interferon-α and interleukin-2—and intravesical bacillus Calmette-Gue´rin (BCG).
However, as recent successes reshape the field, efforts to comprehend and harness precise
mechanisms in immunotherapy will be required.
Breakthroughs in Melanoma
Perhaps the most profound impacts of both immunotherapy and precision medicine, in the
form of targeted therapy, can be appreciated in the transformation of treatment for metastatic
melanoma during the past decade. The discovery of the oncogenic V600E driver mutation in
BRAF, which is present in ~50% of melanomas, led to the development of vemurafenib and
dabrafenib, which are inhibitors of the mutant BRAF kinase [2]. Although targeting mutant
BRAF kinase and inhibiting the downstream mitogen-activated protein kinase (MAPK) path-
way produces high response rates in melanoma patients, the duration of responses is brief [3],
highlighting the need for additional therapies. Meanwhile, preclinical evidence suggested that
blocking negative regulators, or checkpoints, of T cell responses could improve antitumor
immune responses (Fig 1). The first such negative regulator tested was cytotoxic T-lympho-
cyte-associated protein 4 (CTLA-4), a T cell surface receptor that binds with high affinity to
the costimulatory ligands B7-1 and B7-2 found on the surface of antigen-presenting cells. The
interaction with CTLA-4 prevents binding of the costimulatory ligands to cluster of differenti-
ation 28 (CD28), a major costimulatory receptor on the T cell necessary for a robust T cell
response. Despite concerns about uncontrollable autoimmunity resulting from systemic
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CTLA-4 blockade, ipilimumab, a monoclonal antibody against CTLA-4, improved overall sur-
vival in patients with metastatic melanoma [4].
The successes of ipilimumab were quickly followed by trials targeting the immune inhibi-
tory interaction between programmed cell death protein 1 (PD-1), found on T cells, and its
ligand, PD-L1, found on tumor cells. In contrast to the central immune inhibitory effects of
CTLA-4, inhibition through PD-1 predominantly occurs at the periphery, with tumor cells
up-regulating PD-L1 in response to local immune signals such as interferon-γ. In a major
head-to-head clinical trial, pembrolizumab, a monoclonal antibody against PD-1, demon-
strated improved progression-free and overall survival with fewer high-grade adverse events
compared to ipilimumab [5]. Importantly, in a minority of cases, checkpoint inhibition pro-
duces strikingly durable responses, with up to a third of advanced melanoma patients alive at
five years of follow-up [6]. The majority, unfortunately, fail to respond to immunotherapy,
with objective response rates to checkpoint inhibitor monotherapy ranging from 10%–40%,
with PD-1/PD-L1 targeted antibodies benefiting larger proportions of patients [4,5,7]. Because
the mechanisms of CTLA-4 and PD-1 blockade are distinct and potentially complementary,
dual checkpoint blockade increases response rates to around 60%, albeit with significantly
more adverse events [8,9]. In a matter of a few years, immune checkpoint blockade has become
first-line therapy for advanced melanoma and transformed the outlook for patients. Looking
ahead, uncovering predictive markers of response to immunotherapy and ultimately under-
standing the mechanisms of response will be necessary to extend the promise of immunother-
apy to broader groups of cancer patients.
Fig 1. Central and peripheral immune checkpoints. Central immune inhibition occurs as a result of CTLA-
4 binding to the costimulatory B7 ligands found on antigen-presenting cells (APCs) with high affinity,
preventing signaling through CD28. Antibodies targeting CTLA-4 release this checkpoint to allow T cell
activation. Peripheral immune inhibition occurs through binding of the PD-L1 found on tumor cells to the PD-1
receptor on T cells. Antibodies targeting either the ligand or the receptor release this checkpoint.
doi:10.1371/journal.pmed.1002196.g001
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Efforts to uncover the precise mechanisms of immune checkpoint inhibition and identify
patients likely to benefit from treatment are well under way. Pathologists have long recognized
the prognostic significance of tumor-infiltrating lymphocytes [10], and, unsurprisingly, pre-
treatment CD8+ T cell density is associated with favorable response to immune checkpoint
blockade [11]. However, preclinical data suggest that CD8+ T cells in the tumor microenviron-
ment can promote immune inhibition as a result of interferon-γ-mediated induction of PD-L1
on tumor cells [12]. Response to anti-PD1 therapy in melanoma as well as other cancers has
been suggested to positively correlate with tumor expression of PD-L1 [13,14], highlighting
the central role of this ligand in tumor immune evasion, although PD-L1 expression thus far
appears to be an imperfect predictive biomarker of response. A comprehensive understanding
of immunotherapy requires a deeper analysis of the interaction between immune system and
tumor.
Genomics-Guided Advances
The rapid progress in cancer genomics in recent years has enabled a close examination of the
genetic makeup of thousands of individual cancers across the entire spectrum of major cancer
types. Amidst the search for mutations responsible for driving carcinogenesis, it has become
evident that overall mutation rates vary dramatically both within and between cancer types
[15]. While the vast majority of mutations contribute little, if at all, to intrinsic biological func-
tion in tumor development and survival, they represent novel, “non-self” epitopes that, if pro-
cessed and presented, carry the potential to elicit a tumor-specific immune response [16]. By
mining exome sequencing data to predict neoantigens present in a tumor, several groups have
demonstrated a strong correlation between total neoantigen burden and positive response to
immune checkpoint blockade [17,18]. These insights provide a mechanistic rationale to
expand checkpoint inhibition to mismatch repair-deficient cancers of any type, because the
dramatically elevated mutation rates in these cancers produce significantly more neoantigens
and the potential for a more robust immune response [19].
Although the importance of neoantigens is now firmly established, substantial overlap in
neoantigen burden exists between nonresponders and responders, highlighting the need to
more precisely identify the tumor-specific antigens required for a successful immune response.
Emerging evidence suggests that clonal neoantigens—that is, neoantigens present in all cancer
cells—rather than total neoantigen load are critical for T cell recognition and clinical benefit
from checkpoint blockade [20]. The critical neoantigens also need not be shared between
patients. One targeted approach with the potential to improve and increase responses to
checkpoint inhibition is to produce personalized vaccines specific to the neoantigens present
in a patient’s tumor [16,21].
However, selecting and manufacturing the optimal neoantigen vaccines within a clinically
meaningful time frame remains challenging, and successful targeting of tumor neoantigens
requires antigen-specific T cells, which may not be present. Indeed, the efficacy of CTLA-4
blockade likely stems in part from an expansion of the peripheral T cell receptor (TCR) reper-
toire [22], which presumably includes neoantigen-specific TCRs. Nascent experimental and
computational methods may help to resolve the critical TCR–antigen interactions in each
tumor [23,24], providing the critical blueprints for delivering precision immunotherapy.
As the precise mechanisms of immune checkpoint inhibition continue to be unraveled,
great interest has emerged in combining checkpoint blockade with current targeted therapies.
Substantial research on BRAF mutant melanoma indicates that BRAF inhibition synergizes
with immune checkpoint blockade by facilitating T cell recognition of melanoma antigens in a
more favorable tumor microenvironment [25,26]. Although one early trial combining
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immune checkpoint blockade with BRAF inhibition stalled because of hepatotoxicity [27],
many additional trials are ongoing to optimize dosing and sequencing of the combination. An
attractive feature of combining immune checkpoint blockade with targeted therapy is the
potential to leverage current advances in precision medicine to impact many cancer types. For
example, in BRCA1-deficient ovarian cancer, inhibition of poly(ADP-ribose) polymerases
(PARPs), a family of enzymes involved in DNA repair, markedly increases mutational load in
tumor cells and has demonstrated synergistic potential with CTLA-4 blockade [28]. Targeting
driver mutations such as those in the genes encoding c-KIT or epidermal growth factor recep-
tor (EGFR) with specific inhibitors appears to foster antitumor immunity [29,30]. In many
cancers, disrupting tumor angiogenesis by inhibiting vascular endothelial growth factor
(VEGF)/vascular endothelial growth factor receptor (VEGFR) promotes immune cell recruit-
ment and infiltration, which may derive additional benefit from checkpoint inhibition [31]. In
all of these cases and others, clinical trials are ongoing to determine the ability of targeted ther-
apies to potentiate response to immune checkpoint inhibition.
Future of Precision Immunotherapy
Propelled by recent successes, enthusiasm for immunotherapy has surged beyond targeting
CTLA-4 and PD-1 pathways. Many additional immune regulators, both stimulatory and
inhibitory, are being explored as potential targets for cancer immunotherapy, each with a
unique set of advantages and potential risks. Novel insights into neoantigens and combination
with immune checkpoint inhibition have breathed new life into cancer vaccines, which had
been tested for decades with little success. In addition, cell-based therapies may be required in
some patients to elicit a robust antitumor response. Adoptive cell transfer of autologous T cells
selected for tumor reactivity [32] and genetically engineered T cells with chimeric antigen
receptors targeting tumor antigens [33] have demonstrated promise in melanoma and other
cancer types. As new immunotherapies expand the arsenal of cancer therapies, deeper mecha-
nistic insight will be required to inform clinical decisions. The exciting advances toward
understanding and delivering precision immunotherapy are poised to change the way cancer
is treated.
References
1. Coley W. The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten
original cases. Am J Med Sci. 1893; 105:487–511.
2. Holderfield M, Deuker MM, McCormick F, McMahon M. Targeting RAF kinases for cancer therapy:
BRAF-mutated melanoma and beyond. Nat Rev Cancer. 2014; 14(7):455–67. doi: 10.1038/nrc3760
PMID: 24957944
3. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with
vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364(26):2507–16. doi: 10.
1056/NEJMoa1103782 PMID: 21639808
4. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with
ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711–23. doi: 10.1056/
NEJMoa1003466 PMID: 20525992
5. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus Ipilimumab
in Advanced Melanoma. N Engl J Med. 2015; 372(26):2521–32. doi: 10.1056/NEJMoa1503093 PMID:
25891173
6. Hodi FS, Kluger H, Sznol M, Carvajal R, Lawrence D, Atkins M, et al. Abstract CT001: Durable, long-
term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab
(NIVO) monotherapy in a phase I trial. Cancer Research. 2016; 76(14 Supplement):CT001–CT.
7. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated
melanoma without BRAF mutation. N Engl J Med. 2015; 372(4):320–30. doi: 10.1056/NEJMoa1412082
PMID: 25399552
PLOS Medicine | DOI:10.1371/journal.pmed.1002196 December 13, 2016 4 / 6
8. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et al. Nivolumab and ipili-
mumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015; 372(21):2006–17. doi: 10.
1056/NEJMoa1414428 PMID: 25891304
9. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined Nivolumab and
Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015; 373(1):23–34. doi: 10.1056/
NEJMoa1504030 PMID: 26027431
10. Larsen TE, Grude TH. A retrospective histological study of 669 cases of primary cutaneous malignant
melanoma in clinical stage I. 3. The relation between the tumour-associated lymphocyte infiltration and
age and sex, tumour cell type, pigmentation, cellular atypia, mitotic count, depth of invasion, ulceration,
tumour type and prognosis. Acta Pathol Microbiol Scand A. 1978; 86A(6):523–30. PMID: 716913
11. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces
responses by inhibiting adaptive immune resistance. Nature. 2014; 515(7528):568–71. doi: 10.1038/
nature13954 PMID: 25428505
12. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, et al. Up-regulation of PD-L1, IDO, and T
(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med. 2013; 5
(200):200ra116. doi: 10.1126/scitranslmed.3006504 PMID: 23986400
13. Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 ligands, and
other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer
Res. 2014; 20(19):5064–74. doi: 10.1158/1078-0432.CCR-13-3271 PMID: 24714771
14. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treat-
ment of non-small-cell lung cancer. N Engl J Med. 2015; 372(21):2018–28. doi: 10.1056/
NEJMoa1501824 PMID: 25891174
15. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heteroge-
neity in cancer and the search for new cancer-associated genes. Nature. 2013; 499(7457):214–8. doi:
10.1038/nature12213 PMID: 23770567
16. Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, et al. Checkpoint blockade cancer
immunotherapy targets tumour-specific mutant antigens. Nature. 2014; 515(7528):577–81. doi: 10.
1038/nature13988 PMID: 25428507
17. Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, et al. Genomic correlates of
response to CTLA-4 blockade in metastatic melanoma. Science. 2015; 350(6257):207–11. doi: 10.
1126/science.aad0095 PMID: 26359337
18. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical
response to CTLA-4 blockade in melanoma. N Engl J Med. 2014; 371(23):2189–99. doi: 10.1056/
NEJMoa1406498 PMID: 25409260
19. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 Blockade in Tumors with
Mismatch-Repair Deficiency. N Engl J Med. 2015; 372(26):2509–20. doi: 10.1056/NEJMoa1500596
PMID: 26028255
20. McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, et al. Clonal neoantigens
elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016; 351
(6280):1463–9. doi: 10.1126/science.aaf1490 PMID: 26940869
21. Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti AA, et al. Cancer immuno-
therapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T
cells. Science. 2015; 348(6236):803–8. doi: 10.1126/science.aaa3828 PMID: 25837513
22. Robert L, Tsoi J, Wang X, Emerson R, Homet B, Chodon T, et al. CTLA4 blockade broadens the periph-
eral T-cell receptor repertoire. Clin Cancer Res. 2014; 20(9):2424–32. doi: 10.1158/1078-0432.CCR-
13-2648 PMID: 24583799
23. Li B, Li T, Pignon JC, Wang B, Wang J, Shukla SA, et al. Landscape of tumor- infiltrating T cell repertoire
of human cancers. Nat Genet. 2016; 48(7):725–32. doi: 10.1038/ng.3581 PMID: 27240091
24. Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S, et al. Predicting immuno-
genic tumour mutations by combining mass spectrometry and exome sequencing. Nature. 2014; 515
(7528):572–6. doi: 10.1038/nature14001 PMID: 25428506
25. Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, et al. BRAF inhibition is associ-
ated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in
patients with metastatic melanoma. Clin Cancer Res. 2013; 19(5):1225–31. doi: 10.1158/1078-0432.
CCR-12-1630 PMID: 23307859
26. Cooper ZA, Juneja VR, Sage PT, Frederick DT, Piris A, Mitra D, et al. Response to BRAF inhibition in
melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res.
2014; 2(7):643–54. doi: 10.1158/2326-6066.CIR-13-0215 PMID: 24903021
PLOS Medicine | DOI:10.1371/journal.pmed.1002196 December 13, 2016 5 / 6
27. Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J. Hepatotoxicity with combination of vemurafenib
and ipilimumab. N Engl J Med. 2013; 368(14):1365–6. doi: 10.1056/NEJMc1302338 PMID: 23550685
28. Higuchi T, Flies DB, Marjon NA, Mantia-Smaldone G, Ronner L, Gimotty PA, et al. CTLA-4 Blockade
Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer. Cancer Immunol
Res. 2015; 3(11):1257–68. doi: 10.1158/2326-6066.CIR-15-0044 PMID: 26138335
29. Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, et al. Activation of the PD-
1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013; 3
(12):1355–63. doi: 10.1158/2159-8290.CD-13-0310 PMID: 24078774
30. Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, Ocuin LM, Obaid H, et al. Imatinib potentiates
antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med. 2011;
17(9):1094–100. doi: 10.1038/nm.2438 PMID: 21873989
31. Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, et al. Vascular normalizing doses of
antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance
immunotherapy. Proc Natl Acad Sci U S A. 2012; 109(43):17561–6. doi: 10.1073/pnas.1215397109
PMID: 23045683
32. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete
responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunother-
apy. Clin Cancer Res. 2011; 17(13):4550–7. doi: 10.1158/1078-0432.CCR-11-0116 PMID: 21498393
33. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells
for sustained remissions in leukemia. N Engl J Med. 2014; 371(16):1507–17. doi: 10.1056/
NEJMoa1407222 PMID: 25317870
PLOS Medicine | DOI:10.1371/journal.pmed.1002196 December 13, 2016 6 / 6
